Safety of Closed-loop Hybrid Insulin Administration During Ramadan Fasting in People Living With Type 1 Diabetes (RAMDAM)
Evaluation of the Glycemic Profile During the Ramadan Fasting in People With Type 1 Diabetes Treated With Closed-loop Hybrid Insulin System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline TOURTE
- Phone Number: 0161693730
- Email: caroline.tourte@chsf.fr
Study Contact Backup
- Name: Dured DARDARI, MD
- Phone Number: 01 61 69 40 17
- Email: dured.dardari@chsf.fr
Study Locations
-
-
-
Corbeil-essonnes Cedex, France, 91106
- Centre Hospitalier Sud Francilien
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age > 18 years
- type 1 diabetes for > 1 year
- on using closed-loop hybrid insulin administration
- scheduled Ramadan fasting
- patient put on using closed-loop hybrid insulin administration more than 2 months before the start of the Ramadan fast
- percentage of continuous glucose monitoring sensor wear > 70% in at least one of the two 30-day periods
Exclusion Criteria:
- patient put on using closed-loop hybrid insulin administration less than 2 months before the start of the Ramadan fast
- patient who is pregnant or wants to become pregnant immediately
- patient informed of the study who objected to the collection of his/her data.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose time
Time Frame: Day 30
|
time spent in the 3.9-10.0
mmol/l glucose target (TIR)) in the Ramadan period
|
Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose time
Time Frame: Day 60
|
The time spent in the 3.9-10.0
mmol/l glucose target (TIR)) in 30 days prior the Ramadan period
|
Day 60
|
|
Glucose time
Time Frame: Day 30
|
time spent below target 3.9 mmol/l
|
Day 30
|
|
Glucose time
Time Frame: Day 60
|
time spent below target 2.97 mmol/l, between 2.97 and 3.79 mmol/l, between 9.05 mmol/l and 12.5mmol/l and > 12.5 mmol/l
|
Day 60
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dured DARDARI, MD, Centre Hospitalier Sud Francilien
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023/0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.